Aspen Grove Capital’s West Pharmaceutical WST Stock Holding History

Aspen Grove Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,731	Closed	-$388K	–	270
2025 Q1	$388K	Buy	+1,731	New	+$477K	0.07%	134

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Aspen Grove Capital's WST Position: Q2 2025 in Review

Aspen Grove Capital sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 1,731 shares — an estimated $388K sold.

Aspen Grove Capital first reported a position in WST in Q1 2025 and held it in 1 quarter. The position peaked at $388K in Q1 2025. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

Aspen Grove Capital reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Aspen Grove Capital sold 1,731 West Pharmaceutical shares in Q2 2025, an estimated $388K.
Aspen Grove Capital first reported a position in West Pharmaceutical in Q1 2025 and held it in 1 quarter.
Aspen Grove Capital's West Pharmaceutical position peaked at $388K in Q1 2025.
730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on Aspen Grove Capital's 13F filing for Q2 2025, filed 14 Aug 2025.